0.78
-0.1752(-18.44%)
Currency In USD
| Previous Close | 0.95 |
| Open | 1.01 |
| Day High | 1.02 |
| Day Low | 0.73 |
| 52-Week High | 3.06 |
| 52-Week Low | 0.55 |
| Volume | 727,234 |
| Average Volume | 206,800 |
| Market Cap | 8.53M |
| PE | -0.69 |
| EPS | -1.13 |
| Moving Average 50 Days | 0.89 |
| Moving Average 200 Days | 1.06 |
| Change | -0.18 |
If you invested $1000 in Predictive Oncology Inc. (POAI) 10 years ago, it would be worth $0.05 as of September 29, 2025 at a share price of $0.775. Whereas If you bought $1000 worth of Predictive Oncology Inc. (POAI) shares 5 years ago, it would be worth $46.81 as of September 29, 2025 at a share price of $0.775.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Predictive Oncology Announces 1-for-15 Reverse Stock Split
GlobeNewswire Inc.
Sep 25, 2025 12:00 PM GMT
Common Stock Will Begin Trading on Split-Adjusted Basis on September 30, 2025PITTSBURGH, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI), a leader in AI-driven drug development and discovery, today announced that it will
Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients
GlobeNewswire Inc.
Sep 04, 2025 1:00 PM GMT
Collaboration builds upon positive results utilizing Predictive Oncology’s AI platform to identify new indications for existing drugsPITTSBURGH, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug
Predictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx® and Pursuit of Other High-Value AI-Driven Drug Discovery and Development Opportunities
GlobeNewswire Inc.
Jul 15, 2025 1:00 PM GMT
$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives Discussions underway to expand adoption of ChemoFx in the U.S. and accelerate initial launch in Europe